Intellectual Property India Publishes Patent Application for 'HDAC Inhibitor And Use Thereof' Filed by Wigen Biomedicine Technology (SHANGHAI) Co. Ltd.

MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202527063094 A) filed by Wigen Biomedicine Technology (SHANGHAI) Co. Ltd., Shanghai, on July 2, for 'hdac inhibitor and use thereof.'

Inventor(s) include Xu, Ruihua; Wang, Feng; Xie, Yuli; Liu, Wenzhong; and Qian, Lihui.

The application for the patent was published on Sept. 26, under issue no. 39/2025.

According to the abstract released by the Intellectual Property India: "An HDAC inhibitor and the use thereof. Specifically, the present invention relates to a compound as represented by general formula (1) and a preparation method therefor, and the use of the compound of general formula (1) and each isomer, each crystal form, a pharmaceutically acceptable salt, hydrate or solvate thereof as an HDAC inhibitor in the preparation of an anti-tumor drug."

The patent application was internationally filed on Dec. 06, 2023, under International application No.PCT/CN2023/136827.

Disclaimer: Curated by HT Syndication.